论文部分内容阅读
目的探讨奥沙利铂动脉灌注联合卡培他滨治疗晚期胃癌的临床效果。方法 60例新诊断无法手术或不能耐受手术的晚期胃癌患者作为研究对象,将其随机分为对照组和观察组,各30例。其中对照组患者给予奥沙利铂联合卡培他滨静脉化疗,观察组患者给予奥沙利铂动脉灌注联合卡培他滨化疗。比较两组患者的治疗效果、无进展生存期(PFS)、总生存时间(OS)以及不良反应发生情况。结果对照组治疗近期有效率为36.7%,观察组为53.3%,比较差异无统计学意义(P>0.05)。对照组患者PFS为(2.4±0.8)个月,OS为(7.6±2.0)个月;观察组PFS为(3.9±1.2)个月,OS为(9.7±3.5)个月;观察组长于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论奥沙利铂动脉灌注联合卡培他滨治疗对于无法耐受奥沙利铂不良反应的患者可获得更长的PFS和OS,且不增加不良反应,值得临床推广应用。
Objective To investigate the clinical effect of oxaliplatin arterial infusion combined with capecitabine in the treatment of advanced gastric cancer. Methods Sixty patients with newly diagnosed advanced gastric cancer who could not be operated or could not tolerate surgery were randomly divided into control group and observation group, with 30 cases in each group. Patients in the control group were given oxaliplatin combined with capecitabine intravenous chemotherapy. Patients in the observation group were given oxaliplatin arterial infusion combined with capecitabine chemotherapy. The treatment effect, progression-free survival (PFS), overall survival time (OS) and adverse reactions of the two groups were compared. Results The effective rate of the control group was 36.7% and the observation group was 53.3%. There was no significant difference between the two groups (P> 0.05). The PFS in the control group was (2.4 ± 0.8) months and the OS was (7.6 ± 2.0) months in the control group. The PFS in the observation group was (3.9 ± 1.2) months and the OS was (9.7 ± 3.5) months. (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The combination of oxaliplatin arterial infusion and capecitabine can prolong the PFS and OS in patients who can not tolerate oxaliplatin adverse reactions, and does not increase adverse reactions, which is worthy of clinical application.